<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00817284</url>
  </required_header>
  <id_info>
    <org_study_id>BIBT-01</org_study_id>
    <nct_id>NCT00817284</nct_id>
  </id_info>
  <brief_title>Bevacizumab and Irinotecan or Bevacizumab and Temozolomide With Concomitant Radiotherapy for Primary Glioblastoma Multiforme (GBM)</brief_title>
  <official_title>A Randomized Phase II Trial With Bevacizumab, Irinotecan and Cerebral Radiotherapy Versus Bevacizumab, Temozolomide and Cerebral Radiotherapy as First Line Treatment for Patients With Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ulrik Lassen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Significant activity (radiographic response rates of approximately 60%) has recently been&#xD;
      demonstrated in phase II studies in patients with relapsed GBM from the combined use of&#xD;
      Irinotecan (CPT-11) and bevacizumab. The 6-month progression-free survival rate is 30% and&#xD;
      median survival duration is 9 months. The current first line therapy of GBM patients&#xD;
      following initial surgical resection/debulking is the concomitant use of cerebral&#xD;
      radiotherapy and the orally available alkylating agent temozolomide, followed by temozolomide&#xD;
      for 6 months post-radiotherapy.&#xD;
&#xD;
      Considering the significant activity of the combination of Bevacizumab + irinotecan in&#xD;
      patients with recurrent GBM, and considering the activity of temozolomide in GBM, it is&#xD;
      proposed that the combination of Bevacizumab + Temozolomide may also be an active regimen.&#xD;
      Bevacizumab + Temozolomide display non-overlapping toxicity clinically and thus their&#xD;
      combined use without significant dose-reductions seems rational.&#xD;
&#xD;
      The toxicity from the combined use of the two drugs prior to radiotherapy, as well as the&#xD;
      toxicity when administered together with radiotherapy, is evaluated.&#xD;
&#xD;
      This study will try to identity whether Bevacizumab and Irinitecan or Bevacizumab and&#xD;
      Temozolomide should be the experimental arm in future phase III comparison with standard care&#xD;
      with concomitant Temozolomide and radiotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate according to McDonald criteria</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab + Irinotecan and concomitant radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab and Temozolomide and concomitant radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab and Irinotecan and radiotherapy</intervention_name>
    <description>Bevacizumab 10 mg/kg is administered on days 1 and 15.&#xD;
Irinotecan:&#xD;
Irinotecan 125 mg/m2 is administered on days 1 and 15 to patients NOT receiving enzyme-inducing antiepileptic drugs (EIAED).&#xD;
Irinotecan 340 mg/m2 is administered on days 1 and 15 to patients receiving EIAEDs.&#xD;
During concomitant chemoradiotherapy, bevacizumab and irinotecan are given in the same doses and schedules as before and after chemoradiotherapy.&#xD;
Radiotherapy is delivered during 3rd and 4th cycle of chemotherapy and consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week (Monday to Friday) over a period of six weeks for a total dose of 60 Gy.</description>
    <arm_group_label>arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab and Temozolomide and radiotherapy</intervention_name>
    <description>Bevacizumab 10 mg/kg is administered on days 1 and 15. Temozolomide dosing before start concomitant chemoradiotherapy: 150 mg/m2/day on days 1-5 during the first 28 days treatment cycle, then 200 mg/m2/day on the subsequent cycles until radiotherapy.&#xD;
Temozolomide administered concomitantly with the radiotherapy: Temozolomide 75 mg/m2/day for 7 days per week is administered on each day of radiotherapy.&#xD;
After completed chemoradiotherapy, temozolomide is dosed and administered as it was prior to start chemoradiotherapy, i.e. temozolomide 200 mg/m2/day on days 1-5 out of a 28 days schedule, taking into consideration any previous dose-reductions already made.&#xD;
Radiotherapy is delivered during 3rd and 4th cycle of chemotherapy and consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week (Monday to Friday) over a period of six weeks for a total dose of 60 Gy.</description>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Histological verified primary glioblastoma multiforme&#xD;
&#xD;
          -  No prior therapy for GBM, except for primary surgical resection or biopsy&#xD;
&#xD;
          -  PS 0-2&#xD;
&#xD;
          -  Age &gt; 18&#xD;
&#xD;
          -  Expected survival &gt; 3 months&#xD;
&#xD;
          -  Adequate liver, renal and bone-marrow function, determined as:&#xD;
&#xD;
               -  Thrombocytes &gt; 100 x 109/liter&#xD;
&#xD;
               -  Hemoglobin &gt;6.2 mmol/liter&#xD;
&#xD;
               -  Leukocytes &gt; 3 x 109/liter&#xD;
&#xD;
               -  Neutrophil granulocytes &gt; 1.5 x 109/liter&#xD;
&#xD;
               -  ASAT and/or ALAT &lt; 3 x upper normal limit&#xD;
&#xD;
               -  Bilirubin &lt; 1.5 x upper normal limit&#xD;
&#xD;
               -  Serum-creatinin &lt; upper normal limit or glomerular filtration rate &gt;60 ml/min&#xD;
                  (corrected for age) determined by measurement of clearance of Cr-EDTA&#xD;
&#xD;
               -  APTT &lt; upper normal limit&#xD;
&#xD;
               -  INR &lt; upper normal limit&#xD;
&#xD;
          -  Fertile women of childbearing age must use proper anti-conception (oral&#xD;
             contraceptives, IUD and/or condom). Fertile men must use condom&#xD;
&#xD;
          -  No sign of cerebral bleeding on cerebral MR-scanning at baseline.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Previous therapy of GBM, including radiotherapy and the use of biological &quot; targeted&quot;&#xD;
             drug, e.g. drugs targeted against the VEGF- or EGFR pathway&#xD;
&#xD;
          -  Concurrent use of medication that can affect the interpretation of the results from&#xD;
             the study, e.g. use of immunosuppressive drugs, except corticosteroids&#xD;
&#xD;
          -  Conditions (medical, social or physical) that may compromise proper information and/or&#xD;
             follow-up&#xD;
&#xD;
          -  Other concurrent or previous cancer within 5 years, except adequately treated basal or&#xD;
             planocellular skin cancer, or cervical carcinoma in situ&#xD;
&#xD;
          -  Significant heart disease (according to the New York Heart Association class II or&#xD;
             more severe), clinically significant arrhythmia or unstable angina pectoris/acute&#xD;
             myocardial infarction within last 6 months&#xD;
&#xD;
          -  Clinical significant peripheral arterial disease&#xD;
&#xD;
          -  Known or suspected disorders of coagulation or concurrent therapy with ASA, NSAID or&#xD;
             clopidogrel&#xD;
&#xD;
          -  Major surgery, open biopsy or greater trauma, or expectations thereof, within 28 days&#xD;
             prior to start of therapy&#xD;
&#xD;
          -  Minor surgery or needle biopsy, or expectations thereof, within 7 days prior to start&#xD;
             of therapy&#xD;
&#xD;
          -  Known or suspected abdominal fistulas, gastrointestinal perforations or&#xD;
             intra-abdominal abscesses within 6 months prior to start of therapy&#xD;
&#xD;
          -  Chronic inflammatory intestinal disease and/or intestinal obstruction&#xD;
&#xD;
          -  Known or active HIV or Hepatitis B/C infection&#xD;
&#xD;
          -  Concurrent ongoing significant infection or diabetes mellitus not adequately&#xD;
             controlled medically&#xD;
&#xD;
          -  Clinically significant non-healing ulcers&#xD;
&#xD;
          -  Active ventricular or duodenal ulcers within 6 months prior to start of therapy&#xD;
&#xD;
          -  Recent bone-fracture (&lt;3 months)&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Need for systemic anticoagulant therapy at time of start of therapy&#xD;
&#xD;
          -  Blood pressure &gt; 150/100 mmHg (patients are allowed to receive proper antihypertensive&#xD;
             medication)&#xD;
&#xD;
          -  Proteinuria ≥ 1 gram/day&#xD;
&#xD;
          -  Known allergy toward irinotecan (or related substance) or vehicle&#xD;
&#xD;
          -  Known allergy toward temozolomide (or related substance) or vehicle&#xD;
&#xD;
          -  Known allergy toward bevacizumab (or related substance) or vehicle&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Århus Hospital</name>
      <address>
        <city>Århus</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <study_first_submitted>December 8, 2008</study_first_submitted>
  <study_first_submitted_qc>January 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2009</study_first_posted>
  <last_update_submitted>November 29, 2011</last_update_submitted>
  <last_update_submitted_qc>November 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Ulrik Lassen</investigator_full_name>
    <investigator_title>MD., PH.D. Chief Physician, Phase I Unit</investigator_title>
  </responsible_party>
  <keyword>Newly diagnosed patients with glioblastoma multiforme.</keyword>
  <keyword>Performance status 0-2.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

